

**In the Claims:**

Please cancel claims 23-34 without prejudice or disclaimer and add claims 35-64.

**List of Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

1-34. (Cancelled)

35. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects cotton rats against lower respiratory tract infections caused by RSV when administered to cotton rats.

36. (New) The antibody composition of claim 35, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the respiratory syncytial virus (RSV) F protein.

37. (New) The antibody composition of Claim 36, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

38. (New) The antibody composition of Claim 36, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

39. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the respiratory syncytial virus (RSV) F protein and wherein said

antibody composition protects humans against lower respiratory tract infections caused by RSV when administered to humans.

40. (New) The antibody composition of claim 39, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects humans against lower respiratory tract infections caused by RSV when administered to humans.

41. (New) The antibody composition of Claim 40, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

42. (New) The antibody composition of Claim 40, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

43. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the antigenic site A of the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects cotton rats against lower respiratory tract infections caused by RSV when administered to cotton rats.

44. (New) The antibody composition of claim 43, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the antigenic site A of the respiratory syncytial virus (RSV) F protein.

45. (New) The antibody composition of Claim 44, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

46. (New) The antibody composition of Claim 44, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

47. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the antigenic site C of the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects cotton rats against lower respiratory tract infections caused by RSV when administered to cotton rats.

48. (New) The antibody composition of Claim 47, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the antigenic site C of the respiratory syncytial virus (RSV) F protein.

49. (New) The antibody composition of Claim 48, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

50. (New) The antibody composition of Claim 48, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

51. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the antigenic site A of the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects humans against lower respiratory tract infections caused by RSV when administered to humans.

52. (New) The antibody composition of claim 51, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the antigenic site A of the respiratory syncytial virus (RSV) F protein.

53. (New) The antibody composition of Claim 52, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

54. (New) The antibody composition of Claim 52, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

55. (New) A human-murine antibody composition, wherein the antibody in said antibody composition binds to the antigenic site C of the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects humans against lower respiratory tract infections caused by RSV when administered to humans.

56. (New) The antibody composition of claim 55, wherein the antibody in said antibody composition contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody that specifically binds to the antigenic site C of the respiratory syncytial virus (RSV) F protein and wherein said antibody composition protects humans against lower respiratory tract infections caused by RSV when administered to humans.

57. (New) The antibody composition of Claim 56, wherein the antibody in said antibody composition contains at least two CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

58. (New) The antibody composition of Claim 56, wherein the antibody in said antibody composition contains the CDRs from each of the variable heavy and variable light chains of said murine monoclonal antibody against respiratory syncytial virus.

59. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 35.

60. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 39.

61. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 43.

62. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 47.

63. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 51.

64. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising administering to said animal an effective amount of the antibody composition of Claim 55.